<< Back to News

New FDA Approval for KADCYLA

On May 3, 2019, the FDA approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

More Information:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ado-trastuzumab-emtansine-early-breast-cancer

Full Prescribing Information:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf